Adverse events reported included anemia, which developed in 85% of
patients, and rash in 24%. In patients treated with telaprevir, 23%
developed rash, while 0% of patients treated with boceprevir developed
SAN DIEGO — Premature treatment discontinuation because of the high
rate of adverse events is a significant issue with direct-acting
antivirals among hepatitis C patients in clinical practice, a speaker said here.
“Our SVR [sustained virologic response] rates have improved with the advent of direct-acting antivirals [DAA], but there’s still a lot of room to go,” Phillip K. Henderson, DO, clinical instructor of medicine with the University of South Alabama, said at the American College of Gastroenterology Annual Scientific Meeting.